Uncategorised - European Medical Journal

ublituximab

Five Year Outcomes of Ublituximab in Multiple Sclerosis

Long-term ublituximab treatment reduces relapse rates and disability progression, reinforcing early intervention strategies in multiple sclerosis care.

B12

Scientists Find Lab Test Can Explain High Vitamin B12

Macro B12 may explain persistently raised vitamin B12 levels and help avoid unnecessary bone marrow biopsy in patients with low suspicion of malignancy.

Smartphone screen showing mobile instant messaging reminders supporting brief exercise for smoking cessation.

Mobile Instant Messaging for Smoking Cessation Falls Short

A mobile instant messaging exercise-program did not significantly improve lab-verified smoking-cessation overall rates at 6 months.

Tanja Spanic

Fast Five: Tanja Spanic on Patient Advocacy Updates

In this episode, Tanja Spanic shares her perspective on the updated European Code Against Cancer…

Patient speaking with clinician about long-acting injectable antiretroviral therapy for HIV treatment options.

Long-Acting Injectable ART Preferences Emerge

Long-acting injectable antiretroviral therapy may ease pill burden, improve adherence, and privacy in Pakistan, interviews suggest.

Chronic Hepatitis B in Focus

This video is of a symposium held on November 9, 2025, at the American Association for the Study of Liver Disease (AASLD) Annual Meeting…

Handshake

Gilead to acquire CAR-T biotech Arcellx for $7.8bn

The deal is a unified effort to advance a CAR T-cell therapy currently under regulatory review for multiple myeloma.

Two-Thirds of Women Stop Taking Antidepressants During Pregnancy

Nearly two-thirds of women stop taking prescribed antidepressants during pregnancy, a 2026 cross-sectional analysis has found.

DMT Rapidly Reduces Major Depression Symptoms

DMT therapy significantly reduced major depressive disorder symptoms in a phase IIa trial. Learn more about this rapid-acting psychedelic approach.

Bimekizumab Sustains 3-Year Benefits in Psoriasis

Three-year BE RADIANT results highlight durable bimekizumab benefits in plaque psoriasis, improving PROs and QoL. Read more.